Sign inJoin waitlistJoin the waitlist

Yazan Samhouri

Key Faculty · University of Arizona College of Medicine - Phoenix

Credentials: · · · · · · ·

History

University of Arizona College of Medicine - Phoenix
Present
DREXEL UNIVERSITY
Present

Allegheny Health Network Medical Education Consortium
2020–2023
Internal Medicine
Rochester Regional Health
2017–2020
King Hussein Cancer Center
2014–2017
University of Jordan Faculty of Medicine
2008–2012

Research

Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review
Case report · Journal of Oncology Pharmacy Practice · 2021 · First of 5 authors · 21 citations
Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome
Case report · Anticancer Research · 2022 · 19 citations
Intensity of Cancer Care Near the End of Life at a Tertiary Care Cancer Center in Jordan
Journal of Pain and Symptom Management · 2019 · 12 citations

CK
Cyrus Khan
15 papers
SF
Salman Fazal
12 papers
Urwat Vusqa
9 papers · 2 as a resident
John Lister
8 papers
Rodney Wegner
7 papers
CP
Chelsea Peterson
6 papers · 6 as a resident
LA
Lynna Alnimer
6 papers · 5 as a resident
PA
Palash Asawa
6 papers · 6 as a fellow
Zena Chahine
5 papers · 5 as a fellow
RJ
Rahim Jiwani
4 papers · 4 as a fellow
Deep Shah
3 papers · 3 as a resident
Kate Hickmann
3 papers · 1 as a resident

Clinical trials

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Site PI · Recruiting · Phase 3
TScan Therapeutics, Inc.
2026–2029
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Site PI · Recruiting · Phase 2
ImmunoVaccine Technologies, Inc. (IMV Inc.)
2021–2025
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Sub-investigator · Recruiting · Phase 1
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
2025–2028